Transfusion free radical antegrade modular pancreaticosplenectomy of metastatic neuroendocrine tumor of the pancreas in Jehovah's Witness patient
- PMID: 25692122
- PMCID: PMC4325654
- DOI: 10.4174/astr.2015.88.2.106
Transfusion free radical antegrade modular pancreaticosplenectomy of metastatic neuroendocrine tumor of the pancreas in Jehovah's Witness patient
Erratum in
-
ERRATUM: Correction of the 1st and 2nd authors' affiliation: Transfusion free radical antegrade modular pancreaticosplenectomy of metastatic neuroendocrine tumor of the pancreas in Jehovah's Witness patient.Ann Surg Treat Res. 2015 Mar;88(3):178. doi: 10.4174/astr.2015.88.3.178. Ann Surg Treat Res. 2015. PMID: 25741500 Free PMC article.
Abstract
In a popular sense, Jehovah's Witnesses (JW) have their creeds, one of which is refusal of blood transfusion. Such refusal may impinge on their proper management, especially in critical situations. We present a case of successful bloodless multimodality therapy, which was performed for a JW. The patient was a 49-year-old woman and JW who had general weakness 7 days before admission. She was diagnosed with a pancreatic neuroendocrine tumor (PNET) with hepatic metastases. Transcatheter arterial chemoembolization and Sandostatin LAR injection were performed, and then she was given a transfusion-free Radical antegrade modular pancreatosplenectomy sequentially. We gave recombinant human erythropoietin and iron hydroxide sucrose complex daily for five days after surgery. She was discharged at postoperative day 12 without any surgical complications. Multimodality therapy is very important for optimal treatment of PNET. Along with intimate interdepartmental cooperation, careful patient selection and appropriate perioperative management could possibly enhance the surgical outcome.
Keywords: Bloodless medical and surgical procedures; Jehovah's witnesses; Neuroendocrine tumors; Pancreatectomy.
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Figures



References
-
- Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000;190:432–445. - PubMed
-
- Hung JS, Chang MC, Lee PH, Tien YW. Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases? World J Surg. 2007;31:2392–2397. - PubMed
-
- Magner D, Ouellette JR, Lee JR, Colquhoun S, Lo S, Nissen NN. Pancreaticoduodenectomy after neoadjuvant therapy in a Jehovah's witness with locally advanced pancreatic cancer: case report and approach to avoid transfusion. Am Surg. 2006;72:435–437. - PubMed
-
- Halperin DM, Kulke MH. Management of pancreatic neuroendocrine tumors. Gastroenterol Clin North Am. 2012;41:119–131. - PubMed
-
- Strasberg SM, Drebin JA, Linehan D. Radical antegrade modular pancreatosplenectomy. Surgery. 2003;133:521–527. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous